The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.
Christiane Montag, Anna-Lena Bröcker, Samuel Bayer et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders in Germany. Results indicated significant improvements in psychosocial functioning, with adjusted between-group differences in Mini-ICF-APP scores of -3.45 at 24 months and -4.07 at 36 months, favoring the MPP-S group.
Key findings
- Significant improvement in psychosocial functioning with MPP-S plus TAU compared to TAU alone.
- Adjusted between-group difference in Mini-ICF-APP scores of -3.45 at 24 months.
- Adjusted between-group difference in Mini-ICF-APP scores of -4.07 at 36 months.
- Frequency of adverse events was similar between groups.
Why it matters
The study highlights the potential of psychodynamic psychotherapy to enhance psychosocial functioning in patients with schizophrenia-spectrum disorders, addressing a gap in standard care. This could inform treatment strategies and improve patient outcomes.